Summit Therapeutics (SMMT) Price & Analysis

Compare

1,694 Followers

SMMT Stock Chart & Stats

Day’s Range― - ―

52-Week Range$15.55 - $36.91

Previous CloseN/A

Volume1.23M

Average Volume (3M)4.84M

Market Cap

$15.50B

Enterprise Value$15.51B

Total Cash (Recent Filing)$297.87M

Total Debt (Recent Filing)$5.55M

Price to Earnings (P/E)―

Beta2.35

Next Earnings

Nov 05, 2025

EPS Estimate

-0.17

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.76

Shares Outstanding742,846,700

10 Day Avg. Volume4,179,108

30 Day Avg. Volume4,840,768

Financial Highlights & Ratios

PEG Ratio0.84

Price to Book (P/B)32.99

Price to Sales (P/S)0.00

P/FCF Ratio-90.17

Enterprise Value/Market Cap1.00

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-1.03K

Enterprise Value/Ebitda-20.87

Forecast

1Y Price Target

$30.82

Price Target Upside43.82% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering15

Bulls Say, Bears Say

Bulls Say

Clinical TrialsThe HARMONi-6 presentation confirmed for ESMO is expected to lead to stock appreciation on disclosure of detailed PFS data.

Stock ValuationSummit Therapeutics' stock is considered undervalued despite ivonescimab reaching clinical milestones that no PD-1 agent has ever achieved.

Bears Say

Partnership And Market PositionSummit is considered poorly positioned for medium and long-term success with ivonescimab without a partner.

Regulatory ChallengesFDA approval of ivonescimab in EGFRm NSCLC is highly unlikely and HARMONi failed to validate the HARMONi-A signal observed in China.

Summit Therapeutics News

Citi adds ’30-day upside catalyst watch’ on Summit Therapeutics

Citi added a “30-day upside catalyst watch” on shares of Dummit Therapeutics while keeping a Buy rating on...

10d ago

SMMT

Summit Therapeutics initiated with an Underweight at Barclays

Barclays initiated coverage of Summit Therapeutics (SMMT) with an Underweight rating and $13 price target The firm’s cautious...

18d ago

SMMT

Summit Therapeutics initiated with an Underweight at Barclays

Barclays initiated coverage of Summit Therapeutics (SMMT) with an Underweight rating and $13 price target Published first on...

19d ago

SMMT

Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by...

24d ago

AMGN

SMMT

Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by...

25d ago

AMGN

SMMT

Summit Therapeutics falls -24.1%

Summit Therapeutics (SMMT) is down -24.1%, or -$6.27 to $19.71. Published first on TheFly – the ultimate source...

27d ago

SMMT

EchoStar sells spectrum licenses to SpaceX, StubHub to launch IPO: Morning Buzz

The major averages were broadly higher near noon, recovering ground after Friday’s pullback as investors grow increasingly confident...

27d ago

Morning Movers: EchoStar jumps following $17B spectrum deal with SpaceX

Stock futures started the week with a quiet lift, recovering ground after Friday’s pullback as investors grew increasingly...

27d ago

EME

DNTH

Summit Therapeutics announces data from Phase III HARMONi trial

Summit Therapeutics (SMMT) announced data from the Phase III HARMONi trial featuring the novel, potential first-in-class investigational bispecific...

28d ago

SMMT

Promising Outlook for Summit Therapeutics: Buy Rating Driven by Anticipated HARMONi-6 Trial Performance and Share Price Growth

In a report released yesterday, Yigal Nochomovitz from Citi maintained a Buy rating on Summit Therapeutics, with a...

10d ago

SMMT

Summit Therapeutics’ Ivonescimab Shows Promising Trial Results, Offering a Risk-Mitigation Opportunity with a Buy Rating

H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating on Summit Therapeutics today and set a price target...

19d ago

SMMT

Summit Therapeutics Reveals Promising Phase III Trial Results

Summit Therapeutics ( ($SMMT) ) just unveiled an announcement. On September 7, 2025, Summit Therapeutics announced promising data...

27d ago

SMMT

Summit Therapeutics’ Ivonescimab: Promising Efficacy and Market Potential Reinforce Buy Rating

Mitchell Kapoor, an analyst from H.C. Wainwright, reiterated the Buy rating on Summit Therapeutics. The associated price target...

27d ago

SMMT

Positive Buy Rating for Summit Therapeutics Driven by Promising HARMONi Trial Results and Anticipated Stock Upside

UBS analyst David Dai has maintained their bullish stance on SMMT stock, giving a Buy rating yesterday. David...

27d ago

SMMT

SMMT FAQ

What was Summit Therapeutics’s price range in the past 12 months?

Summit Therapeutics lowest stock price was $15.55 and its highest was $36.91 in the past 12 months.

What is Summit Therapeutics’s market cap?

Summit Therapeutics’s market cap is $15.50B.

When is Summit Therapeutics’s upcoming earnings report date?

Summit Therapeutics’s upcoming earnings report date is Nov 05, 2025 which is in 31 days.

How were Summit Therapeutics’s earnings last quarter?

Summit Therapeutics released its earnings results on Aug 11, 2025. The company reported -$0.76 earnings per share for the quarter, missing the consensus estimate of -$0.091 by -$0.669.

Is Summit Therapeutics overvalued?

According to Wall Street analysts Summit Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Summit Therapeutics pay dividends?

Summit Therapeutics does not currently pay dividends.

What is Summit Therapeutics’s EPS estimate?

Summit Therapeutics’s EPS estimate is -0.17.

How many shares outstanding does Summit Therapeutics have?

Summit Therapeutics has 742,846,700 shares outstanding.

What happened to Summit Therapeutics’s price movement after its last earnings report?

Summit Therapeutics reported an EPS of -$0.76 in its last earnings report, missing expectations of -$0.091. Following the earnings report the stock price went down -9.097%.

Which hedge fund is a major shareholder of Summit Therapeutics?

Currently, no hedge funds are holding shares in SMMT

Summit Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

-328.30%

Trailing 12-Months

Asset Growth

-5.21%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Summit Therapeutics

Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.

Summit Therapeutics (SMMT) Earnings & Revenues

Historic Earnings Reports

SMMT Stock 12 Month Forecast

Average Price Target

$30.82

▲(43.82% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"11":"$11","21":"$21","31":"$31","41":"$41","51":"$51"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":50,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$50.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":30.82,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$30.82</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$13.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[11,21,31,41,51],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,23.84,25.852307692307694,27.864615384615384,29.876923076923077,31.88923076923077,33.901538461538465,35.91384615384615,37.926153846153845,39.93846153846154,41.95076923076923,43.963076923076926,45.97538461538461,47.98769230769231,{"y":50,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,23.84,24.376923076923077,24.913846153846155,25.450769230769232,25.987692307692306,26.524615384615384,27.06153846153846,27.59846153846154,28.135384615384616,28.67230769230769,29.20923076923077,29.746153846153845,30.283076923076923,{"y":30.82,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,23.84,23.006153846153847,22.172307692307694,21.338461538461537,20.504615384615384,19.67076923076923,18.836923076923078,18.003076923076925,17.16923076923077,16.335384615384616,15.501538461538463,14.667692307692308,13.833846153846155,{"y":13,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":12.98,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.1,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.99,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.49,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.84,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.5,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.69,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.8,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.67,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.72,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.2,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.07,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.84,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >